InsidersTradesSigma
Follow the Tandem Diabetes Care, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was disclosed on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MARK NOVARA. All data is free.
Analysts rate Tandem Diabetes Care, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Tandem Diabetes Care, Inc. 是一家专注于开发糖尿病管理医疗设备的公司。它致力于创新解决方案，以提高糖尿病患者的生活质量。